Spyre Therapeutics (SYRE) Total Non-Current Liabilities (2015 - 2026)

Spyre Therapeutics has reported Total Non-Current Liabilities for 12 years, with the latest figure at $91.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 29.96% year-over-year to $91.9 million; the trailing twelve-month figure through Mar 2026 stood at $91.9 million (up 29.96% YoY), and the FY2025 full-year result was $35.9 million, down 33.66% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $91.9 million, up from $35.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $91.9 million in Q1 2026, with the low at $20.8 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $47.4 million across 5 years, with a median of $43.8 million in 2023.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 294.3% — and 2024, when it plunged 75.12%.
• Spyre Therapeutics' Total Non-Current Liabilities stood at $20.8 million in 2022, then soared by 53.45% to $32.0 million in 2023, then jumped by 69.05% to $54.1 million in 2024, then sank by 33.66% to $35.9 million in 2025, then surged by 156.1% to $91.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $91.9 million (Q1 2026), $35.9 million (Q4 2025), and $46.3 million (Q3 2025), per Business Quant data.